1.Development of an Environmental Temperature Supervising Network System
Chinese Medical Equipment Journal 2004;0(09):-
This paper introduces the principles of an Environmental Temperature Supervising Network System, explain its hardware and software structure and the function of network system. The whole system is proved stable and reliable by experiment. It may have some profit in the market and great future in the application.
3.Low-dose tadalafil combined with Shuganyiyang capsules for mild-to-moderate erectile dysfunction.
Ke-Bing YANG ; Xiao-Jun HUANG ; Shi-Geng ZHANG ; Gang CHEN ; Jun FU ; Bo-Dong LÜ
National Journal of Andrology 2014;20(3):267-272
OBJECTIVETo observe the clinical effect of low-dose once-daily tadalafil combined with Shuganyiyang Capsules in the treatment of mild-to-moderate erectile dysfunction (ED).
METHODSNinety patients with mild-to-moderate ED were equally randomized to groups A, B and C to receive Shuganyiyang Capsules, tadalafil, and tadalafil + Shuganyiyang Capsules, respectively. The scores of the patients on IIEF-5 and SF-PAIRS (15-Item Short Form of Psychological Interpersonal Relationship Scales) were recorded before and at 1 and 3 months after treatment.
RESULTSThe IIEF-5 scores of groups A, B and C were 10.13 +/- 1.55, 11.00 + 1.60 and 10.73 +/- 1.91 before treatment, and 13.77 +/- 2.11, 17.77 +/- 2.13 and 17.17 +/- 3.84 at 1 month after treatment, significantly higher in B and C than in A (P <0. 001) , but with no remarkable difference between B and C (P =0. 411). At 3 months after treatment, the IIEF-5 scores were 15.77 +/- 2.05, 18.07 +/- 2.24 and 19.37 +/- 3.76 in the three groups, dramatically higher in B and C than in A (P <0.001) as well as in C than in B (P<0.05). The scores on sexual self-confidence, sexual spontaneity and time concerns in SF-PAIRS were 3.90 +/-0.80, 8.67 +/- 1.94 and 14.43 +/- 1.92 before medication, 5.83 +/- 1.02, 9.90 +/- 1.75 and 11.17 +/- 1.68 at 1 month and 6.73 +/- 0.98, 11.07 +/- 2.08 and 10.67 +/-1.60 at 3 months after medication in group A; 4.17 +/- 0.87, 9.37 +/-1.43 and 14.47 +/-1.57 before medication, 6.47 +/-0.78, 10.83 +/- 2.18 and 10.20 +/-1.56 at 1 month and 6.83 +/-0.91, 11.30 +/- 1.88 and 9.47 +/- 1.57 at 3 months in group B; and 4.23 +/-0. 94, 9.50 +/- 1.89 and 14.67 +/- 2.91 before medication, 8.03 +/- 1.67, 13.43 +/-1.10 and 9.70 +/-1.21 at 1 month and 8.93 +/- 1.78, 14.70 +/- 1.26 and 8. 87 +/- 0. 97 at 3 months in group C. Compared with the baseline, the SF-PAIRS scores of the three groups were all significantly improved after treatment (P <0. 05) , and markedly higher in C than in the other two groups (P <0.05).
CONCLUSIONLow-dose once-daily tadalafil combined with Shuganyiyang Capsules is obviously effective in the treatment of mild-to-moderate ED, which not only improves the patients'erectile function, sexual self-confidence and sexual spontaneity, but also reduces their time concerns.
Adult ; Carbolines ; administration & dosage ; therapeutic use ; Drugs, Chinese Herbal ; therapeutic use ; Erectile Dysfunction ; drug therapy ; Humans ; Male ; Tadalafil ; Treatment Outcome
4.Liver transplantation for cholangiocarcinoma in 6 patients
Hong FU ; Liang XIAO ; Guoshan DING ; Zhijia NI ; Xiaomin SHI ; Wenyuan GUO ; Xiaogang GAO ; Jun MA ; Zhengxin WANG ; Zhiren FU
Chinese Journal of General Surgery 2008;23(7):490-492
Objective To evaluate the therapeutic effects of liver transplantation (LT) for cholangiocarcinoma(CC)and analyze the prognostic factors.Methods From December 2001 to December 2006,234 patients receiving LT for hepatic carcinoma in our institute were enrolled as a basis of comparative study for 6 CC patients undergoing LT during the same period.Results These 6 patients were followed-up from 1 to 56 months.Five patients died and one recurred.The 0.5-,1-and 2-year patient cumulative survival rates were 4/6,3/6 and 1/6,respectively.The 0.5-,1-and 2-year tumor-free survival rates were 3/6,2/6 and 1/6,respectively.The average patient or tumor-free survival time were both(14±4) months.Conclusion The prognosis of cholangioearcinoma patients after LT iS poor.
6.Quantitative study on depth of ketamine anesthesia for preschoolers
rong-guo, LIU ; wei-fu, LEI ; jin-gui, YU ; jun-zhang, DU ; shi-da, YING
Journal of Applied Clinical Pediatrics 2004;0(11):-
Objective To compare and quantify the determinants in quantitative electroencephalogram(q-EEG) and heart rate variability power spectrum analysis(HRV-PSA) of ketamme(KTM) anesthesia for preschoolers. Methods Seventy four cases were selected and assigned into 3 groups named A(4-5 years), B(5-6 years), C(6-7 years), 22,28,24 cases in every group respectively. All cases were induced with KTM 5 mg /kg intramuscularly and changes of determinants were recorded continuously. If body movement happened, KTM would be injected with 1 mg/kg. Results On pre- anesthesia, BIS in group A was the least among 3 groups, while LF/HF and HRVI were the largest(P
7.ALK-positive large B-cell lymphoma: report of a case.
Hong YU ; Jun-xing HUANG ; Chao-fu WANG ; Da-ren SHI
Chinese Journal of Pathology 2011;40(8):561-562
Adult
;
Antibodies, Monoclonal
;
metabolism
;
Antineoplastic Combined Chemotherapy Protocols
;
therapeutic use
;
Cyclophosphamide
;
therapeutic use
;
Diagnosis, Differential
;
Doxorubicin
;
therapeutic use
;
Follow-Up Studies
;
Humans
;
Leukocyte Common Antigens
;
metabolism
;
Lymphoma, Large B-Cell, Diffuse
;
drug therapy
;
metabolism
;
pathology
;
Male
;
Mucin-1
;
metabolism
;
Prednisone
;
therapeutic use
;
Receptor Protein-Tyrosine Kinases
;
metabolism
;
Vincristine
;
therapeutic use
8.Comparison between microinvasive puncture and small bone window craniotomy in the treatment of moderate cerebral hemorrhage
Wenxue WANG ; Jun WANG ; Dezhong ZHAI ; Yuliang LIU ; Dianqin SHI ; Guanghui FU ; Fengli LI
Chinese Journal of Postgraduates of Medicine 2009;32(35):7-10
Objective To evaluate and compare the curative effect between the microinvasive craniopuncture therapy and the clearance of hematoma by craniotomy with small bone flap in treating patients with moderate cerebral hemorrhage (30-60 ml)in the basal ganglion part of the brain. Methods Ninety-five patients with intracerebral hemorrhage were randomly divided into treatment group (microinvasive craniopuncture therapy) and control group (the clearance of hematoma by craniotomy with small bone flap). The main indexes of evaluation were the neurological impairment degree (NID) on the 14th day after treatment, activities of daily living (ADL) by the end of the third month, the incidence rate of complications, and the case fatality during 3 months. Results On the 14th day after treatment, there was no significant difference between the two groups in the NID and the ADL of patients. The incidence rate of respiratory tract infection, gastrointestinal hemorrhage, electrolyte disorder in treatment group [16.33% (8/49), 6.12% (3/49), 6.12% (3/49), respectively] was significantly reduced than those of control group [56.52% (26/46), 21.74%(10/46), 21.74% (10/46),respectively] during hospitalization (P < 0.05). By the end of the third month, there was significant difference in favorable outcomes (Barthel index 95-100) (χ~2 = 18.7524,P =0.0009) and in improving the ADL (MRS)(t =5.2723,P =0.0001) between the two groups [39.13% (18/46), 4.65% (2/43),respectively]. In ease fatality, there was no significant difference between the two groups [6.12% (3/49),6.52% (3/46),respectively]. Conclusion As compared with the clearance of hematoma by craniotomy with small bone flap, the microinvasive craniopuncture therapy can remarkably reduce the incidence of complications, and improve the ADL of patients with moderate cerebral hemorrhage (30-60 ml) in the basal ganglion, and decrease disability without increasing fatality.
9.Spindle cell variants of diffuse large B cell lymphoma: report of 2 cases.
Jun-chen WANG ; Da-ren SHI ; Xue-lian FU ; Chang-li LU ; Wan-ping LU
Chinese Journal of Pathology 2005;34(1):55-56
Antineoplastic Combined Chemotherapy Protocols
;
therapeutic use
;
Breast
;
pathology
;
Breast Neoplasms
;
drug therapy
;
pathology
;
Cyclophosphamide
;
therapeutic use
;
Diagnosis, Differential
;
Doxorubicin
;
therapeutic use
;
Female
;
Follow-Up Studies
;
Humans
;
Lymphoma, B-Cell
;
drug therapy
;
pathology
;
Lymphoma, Large B-Cell, Diffuse
;
drug therapy
;
pathology
;
Male
;
Middle Aged
;
Prednisone
;
therapeutic use
;
Sarcoma
;
pathology
;
Spleen
;
pathology
;
Splenic Neoplasms
;
drug therapy
;
pathology
;
Vincristine
;
therapeutic use